Search
Clarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with am...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: CLARITHROMYCIN 1A PH 250MG, CLARITHROMYCIN 1A PH 500MGChloroxylenol
go.drugbank.com/drugs/DB11121ApprovedChloroxylenol, or para-chloro-meta-xylenol (PCMX), is an antiseptic and disinfectant agent used for skin disinfection and surgical instruments. It is found in antibacterial soaps, wound-cleansing applications, and household antiseptics. ...
Synonyms: p-chloro-m-xylenol, p-chloro-3,5-xylenolProducts: Ps-1000, Purgo Ultra PCNicotinamide
go.drugbank.com/drugs/DB02701ApprovedInvestigationalAn important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent n...
Mixtures: BOTA C Reset, PR Natal 430Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 SubstratesMometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: MOMETASONFUROAT 1A PH 50UGNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1Rosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalstatin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: ROSUVASTATIN HEC PH 5MG, ROSUVASTATIN HEC PH 10MGPyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedPyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for nor...
Mixtures: PR Natal 430, Virt-PnCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigational[A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative … the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors